ADMA Biologics vs Roivant Sciences
Add, change or remove companies; up to four.
The short version
- ADMA Biologics is the larger business, with $510M of revenue in fiscal 2025 against $8.3M for Roivant Sciences, about 61 times as much.
- ADMA Biologics grew revenue faster (19.6%, against β71.6%).
- ADMA Biologics kept more of each dollar of sales as operating profit (37.5% operating margin, against β6,235.7%).
- ADMA Biologics turned more of its sales into free cash flow (5.5% FCF margin, against β9,183.5%).
- ADMA Biologics earned a higher return on the capital invested in it (39.5%, against β62.6%).
| Latest fiscal year | ADMA Β· FY25 | ROIV Β· FY25 |
|---|---|---|
| Size | ||
| Market cap | $2.5B | $26.3B |
| Revenue | $510M | $8.3M |
| Free cash flow | $27.8M | β$759M |
| Net income | $147M | β$300M |
| Growth | ||
| Revenue growth | 19.6% | β71.6% |
| 5-year growth | 64.6% | β19.0% |
| Share count change | 0.6% | β4.4% |
| Profitability | ||
| Gross margin | 57.4% | β |
| Operating margin | 37.5% | β6,235.7% |
| Net margin | 28.8% | β3,629.2% |
| FCF margin | 5.5% | β9,183.5% |
| Return on capital | 39.5% | β62.6% |
| Return on equity | 35.6% | β6.5% |
| Balance sheet | ||
| Net debt | β$15.5M | β$4.3B |
| Net debt / EBITDA | β0.1x | β |
| Dividends and buybacks | $31.9M | $0.0M |
| Valuation & quality | ||
| P/E | 15.3x | β |
| Piotroski F-score | 5 | 1 |
Revenue
FY16
ADMA $10.7M
ROIV β
FY17
ADMA $22.8M
ROIV β
FY18
ADMA $17.0M
ROIV β
FY19
ADMA $29.3M
ROIV β
FY20
ADMA $42.2M
ROIV $23.8M
FY21
ADMA $80.9M
ROIV $55.3M
FY22
ADMA $154M
ROIV $31.5M
FY23
ADMA $258M
ROIV $32.7M
FY24
ADMA $427M
ROIV $29.1M
FY25
ADMA $510M
ROIV $8.3M
ADMA
ROIV
Operating margin
FY16
ADMA β162.6%
ROIV β
FY17
ADMA β172.7%
ROIV β
FY18
ADMA β355.0%
ROIV β
FY19
ADMA β141.1%
ROIV β
FY20
ADMA β153.8%
ROIV β4,500.5%
FY21
ADMA β72.1%
ROIV β2,444.8%
FY22
ADMA β25.6%
ROIV β2,875.9%
FY23
ADMA 8.4%
ROIV 13,746.9%
FY24
ADMA 32.6%
ROIV β3,453.3%
FY25
ADMA 37.5%
ROIV β6,235.7%
ADMA
ROIV
Free cash flow
FY16
ADMA β$18.3M
ROIV β
FY17
ADMA β$40.0M
ROIV β
FY18
ADMA β$64.8M
ROIV β
FY19
ADMA β$80.0M
ROIV β
FY20
ADMA β$115M
ROIV β$558M
FY21
ADMA β$126M
ROIV β$695M
FY22
ADMA β$73.4M
ROIV β$856M
FY23
ADMA $4.0M
ROIV β$767M
FY24
ADMA $110M
ROIV β$844M
FY25
ADMA $27.8M
ROIV β$759M
ADMA
ROIV
Return on capital
FY16
ADMA β
ROIV β
FY17
ADMA β
ROIV β
FY18
ADMA β
ROIV β
FY19
ADMA β
ROIV β
FY20
ADMA β82.2%
ROIV β
FY21
ADMA β29.7%
ROIV β
FY22
ADMA β15.8%
ROIV β286.2%
FY23
ADMA 8.1%
ROIV β
FY24
ADMA 52.2%
ROIV β
FY25
ADMA 39.5%
ROIV β62.6%
ADMA
ROIV
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.